Apellis Pharmaceuticals, which is developing a novel protein inhibitor for eye and blood diseases, raised $150 million by offering 10.7 million shares at $14, within the range of $13 to $15. Apellis Pharmaceuticals plans to list on the Nasdaq under the symbol APLS. Citi, J.P. Morgan and Evercore ISI acted as lead managers on the deal.
